InflaRx N.V.

InflaRx Reports Third Quarter 2019 Financial & Operating Results

InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa (news with additional features)

InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa

InflaRx announces appointment of Tony Gibney to its Board of Directors

InflaRx presents at two scientific conferences in February, 2018

InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa

InflaRx to Present at Upcoming Investor Conferences

InflaRx Announces Pricing of Initial Public Offering

InflaRx announces a $ 55M Series D financing and investment round to foster its clinical stage complement anti-C5a development programs

InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa

InflaRx Promotes Othmar Zenker, M.D. to Newly Created Position of Chief Medical Officer

InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa

InflaRx raises EUR 31 million (US$ 34M) in a Series C financing round to foster complement inhibitor development

InflaRx GmbH: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery

InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody